Recently, the cornerstone of medicine (2616, HK) announced that selective inhibitors of RET Phuket, Hua ® (imatinib Pula capsules) Indications application has been extended Chinese State Drug Administration (NMPA) acceptance and inclusion in the priority review The extended indications include advanced or metastatic transfection rearrangement (RET) gene mutation medullary thyroid carcinoma (MTC) that requires systemic treatment, and those that require systemic treatment and are refractory to radioactive iodine (if radioactive iodine is suitable) Advanced or metastatic RET fusion-positive thyroid cancer.
Thyroid cancer is the most common endocrine malignant tumor, and its incidence has increased significantly in recent years.
According to the data released by the National Cancer Center in 2019, the incidence of thyroid cancer ranks 4th among all malignant tumors among women in urban areas in my country, and the 7th overall incidence of cancer types.
There are about 90,000 new cases of thyroid cancer in China each year, and about 6,800 deaths.
Thyroid cancer is clinically divided into papillary carcinoma, follicular carcinoma, undifferentiated carcinoma and medullary carcinoma and other pathological types.
Different types of thyroid cancer are different according to their tumor characteristics, treatment methods and prognosis.
RET fusion and activating mutations are key disease drivers in many cancer types, including NSCLC and many types of thyroid cancer.
About 10-20% of patients with papillary thyroid cancer (the most common thyroid cancer) carry RET fusion, and about 50-90% of patients with advanced MTC (about 2-5% of thyroid cancer) carry RET mutations.
The Phuket Hua ® Extended indications of acceptance is a global clinical research phase I / II ARROW-based study designed to evaluate the integration of Pula imatinib in RET-positive non-small cell lung cancer, thyroid cancer as well as other carry RET mutation Safety, tolerability and effectiveness in patients with advanced solid tumors.